Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
Inventors
Tadayon, Abdolsamad • Huang, Ping • Deng, Chaoyi • Yang, Jinsuo • Lu, Qingqing • Cui, Lin • Jia, Mo • You, Xianjun • Hesson, David P. • JIANG, Siyi
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The invention provides compositions containing a stable crystalline form of brequinar and methods of making such composition. The invention also provides methods of using such compositions to treat a condition in a subject.
Core Innovation
The disclosed subject matter relates to pharmaceutical compositions comprising brequinar sodium salt enriched in polymorphic form C, optionally including a hydrate. The disclosure emphasizes a crystalline form that is stable under ambient conditions to enable reproducible commercial solid oral formulations and broad routes of administration. The document connects this crystalline polymorphic form to dihydroorotate dehydrogenase (DHODH) inhibition through a pyrimidine synthesis blockade via dihydroorotate (DHO).
A central technical aspect is a method of making a crystal comprising at least 80% polymorphic form C of brequinar sodium salt. The method combines a solid form of brequinar acid, sodium hydroxide (NaOH), and a solvent comprising isopropanol and water to produce a solution, followed by removal of insoluble material. Crystallizing is performed using sequential steps including adding a seed crystal of polymorphic form C, producing an alkane-containing mixture by addition of n-heptane, and incubating the alkane-containing mixture at from about 15° C. to about 35° C.
The crystallization process further includes removing the solvent from the seeded mixture at a temperature below ambient temperatures, where the removing step results in a crystal comprising at least 80% polymorphic form C as measured by X-ray Diffraction (XRD). The disclosure describes characterization and selection using XRPD, DSC, and TGA, including observations that patterns B/D/E/F/G/I/J convert to form C, and provides an example outcome with form-C purity and characterization results.
Claims Coverage
The independent claim covers a crystallization method that produces a brequinar sodium salt crystal enriched to at least 80% polymorphic form C by using a specific solution preparation and a sequential crystallizing workflow measured by X-ray Diffraction (XRD), with dependent claims further tightening solvent, stoichiometry, and crystallization conditions.
Seeded polymorphic form C crystallization workflow with n-heptane
Crystallizing brequinar sodium salt to produce a crystal comprising polymorphic form C of brequinar sodium salt by sequentially adding a seed crystal of polymorphic form C to the solution, adding n-heptane to produce an alkane-containing mixture, and incubating the alkane-containing mixture at from about 15° C. to about 35° C.
Below-ambient solvent removal to achieve form C enrichment
Removing the solvent from the seeded mixture at a temperature below ambient temperatures, wherein the removing step results in a crystal comprising at least 80% polymorphic form C as measured by X-ray Diffraction (XRD).
Isopropanol/water solution preparation from brequinar acid and NaOH
Combining a solid form of brequinar acid, sodium hydroxide (NaOH), and a solvent comprising isopropanol and water to produce a solution and removing insoluble material from the combined brequinar acid, NaOH, and solvent before crystallizing.
Quantified polishing constraints in dependent claims for form C purity and conditions
Using dependent refinements that specify ranges for the solvent composition (isopropanol to water), NaOH molar equivalents, incubation time for the alkane-containing mixture, and crystallization temperature ranges, and tightening the polymorphic form C purity threshold measured by XRD to at least 85%, 90%, or 95%.
Across the independent claim and its dependents, the inventive coverage centers on producing brequinar sodium salt crystals enriched in polymorphic form C by preparing a brequinar acid/NaOH/isopropanol-water solution, performing seeded crystallization with n-heptane and controlled incubation, and removing solvent below ambient temperatures to reach an XRD-measured form-C enrichment level, with dependent claims tightening solvent composition, stoichiometry, time, temperature, and purity thresholds.
Stated Advantages
Provides pharmaceutical compositions comprising brequinar sodium salt enriched in polymorphic form C with stability under ambient conditions.
Enables reproducible commercial solid oral formulations.
Supports broad routes of administration.
Documented Applications
Treatment of cancers and viral infections, including adenovirus, coronavirus, SARS-CoV-2, influenza, and rhinovirus.
Interested in licensing this patent?